Quality by Design is the methodical method to development concept that starts with the predefined objects. The method put emphasis on the process of development of a product, the control process, which is built on risk management and comprehensive knowledge of science. The concept of QbD applied to analytical method development is known now as AQbD (Analytical Quality by Design). Comprehension of the Analytical Target Profile (ATP) and the risk assessment for the variables that can have an impact on the productivity of the developed analytical method can be the main principles of the AQbD. Inside the method operable design region (MODR), the AQbD permits the movements of the analytical methods. This paper has been produced to discuss various views of analytical scientists, the comparison with conventional methods, and the phases of the analytical techniques.

The development of dosage forms necessitates the evaluation of pharmacokinetics and pharmacodynamics (PK/PD), which aids scientists in elucidating the drug's mechanism of action and achieving optimal composite design. The incorporation of pharmacokinetic/pharmacodynamic (PK/PD) efficacy studies in the early phases of lead identification and optimisation within drug development can markedly expedite the selection of the most promising dosage forms. The rapid advancement of computer hardware, software, and algorithms, along with drug screening and PK/PD evaluation, has significantly benefited from various computational methods, which substantially decrease the time and cost associated with drug development. Computational pharmacokinetic/pharmacodynamic modelling enhances the translation of in vitro compound potency to in vivo contexts and minimises the necessity for in vivo animal studies. This review seeks to provide people unfamiliar with the insilico program with a fundamental understanding of its main principles. This review initially examines the significance of insilico software in PK/PD evaluation, covering its history, applications, developers, and the latest version. The second part focusses on the use of GastroPlusTM to illustrate the absorption pathway through pre-formulation data. The input data encompassed a physico-chemical evaluation of the drugs, which included measurements of drug solubility in simulated physiological conditions and the assessment of permeability, with some examples (R1315 - Sertraline - piroxicam).

Background/Objectives: Rebamipide is a gastroprotective agent with poor aqueous solubility and rapid gastrointestinal clearance, leading to reduced therapeutic efficiency. This study aimed to enhance the solubility, mucoadhesion, and sustained oral delivery of Rebamipide through the development of a deep eutectic mixture (DEM)-based bioadhesive controlled-release granule formulation. Methods: In silico hydrogen-bonding interactions between Rebamipide, malonic acid, and urea were analyzed using CCDC tools. A thermodynamically stable DEM (1:3:1) was prepared and incorporated into bioadhesive granules using chitosan and HPMC. Physicochemical characterization was conducted using FTIR, DSC, TGA, and PXRD. Solubility, in vitro dissolution, ex vivo mucoadhesion (sheep gastric mucosa), and in vivo gastric retention (BaSO₄-loaded granules in rats) were evaluated. Results: The optimized DEM significantly enhanced Rebamipide solubility (10.08 mg/mL vs. 0.045 mg/mL). Solid-state analyses confirmed hydrogen-bond formation and reduced crystallinity. DEM granules exhibited sustained drug release over 24 h (99.7 ± 0.8%) with improved dissolution efficiency compared to the marketed tablet (Mucosta®, 100 mg; T₅₀%: 5.03 h vs. 0.82 h). Kinetic modeling indicated non-Fickian anomalous transport (n = 0.47). The bioadhesive force of DEM granules (0.29 ± 0.02 N) was significantly higher than that of the pure drug and physical mixture. In vivo radiographic studies confirmed prolonged gastric retention. Conclusions: The DEM-based bioadhesive granule system effectively improves solubility, dissolution rate, mucoadhesion, and gastric retention of Rebamipide. This approach represents a promising platform for once-daily gastroretentive oral delivery, pending further pharmacokinetic evaluation.